AI assistant
Medicus Pharma Ltd. — Director's Dealing 2025
Jul 24, 2025
34562_dirs_2025-07-24_e0c4747b-4980-40fb-b075-505b2f4daeb8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Medicus Pharma Ltd. (MDCX)
CIK: 0001997296
Period of Report: 2025-07-22
Reporting Person: Brennan Edward J. (Chief Scientific Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-07-22 | Stock Option (right to buy) | $3.08 | A | 50000 | Acquired | 2030-07-22 | Common Shares (50000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.75 | 2029-12-17 | Common Shares (20000) | 20000 | Direct |
Footnotes
F1: Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
F2: The board of directors of Medicus Pharma Ltd. (the ?Board?) approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest quarterly in four equal installments over one year from the initial grant date of December 17, 2024. All these options are now vested.
F3: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year.